Clinical pharmacology of dobutamine and dopamine in preterm neonates
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | MedicalExpress (São Paulo. Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000500275 |
Resumo: | Dobutamine is a β1 selective stimulant. β Receptor agonists are used to stimulate the rate and the force of cardiac contraction. The chronotropic effect is useful for the treatment of arrhythmias whereas the inotropic effect is useful to augment the myocardial contractility. Dobutamine is about four times as potent as dopamine in stimulating myocardial contractility in low concentrations and increases left ventricular output in the hypotensive preterm infants. Dobutamine possesses a center of asymmetry. The (-)-isomer of dobutamine is a potent agonist of α1 receptors and is capable of causing marked pressor responses. In contrast, (+)-dobutamine is a potent α1 receptor antagonist which can block the effects of (-)-dobutamine. Dobutamine is relatively cardioselective at dosages used in clinical practice with its main action being on β1-adrenergic receptors. Dobutamine and dopamine undergo intense metabolism in neonates where they are conjugated with sulphate and O-methylated. The clearance and the half-life of dobutamine and dopamine range over one order of magnitude in neonates. Dopamine is widely used to increase blood pressure, cardiac output, urine output and peripheral perfusion in neonates with shock and cardiac failure. Dopamine is more effective than dobutamine in the short-term treatment of systemic hypotension in preterm infants. High doses of dopamine cause vasoconstriction, increase systemic vascular resistance, and, eventually, decrease renal blood flow. Treatment with dobutamine is associated with a significantly greater increase in left ventricular output in the single study reporting that outcome. Dobutamine is indicated for the short-term treatment of cardiac decompensation. |
id |
METC-1_2e8b80f470d2c00f7add6290dfdd0366 |
---|---|
oai_identifier_str |
oai:scielo:S2358-04292014000500275 |
network_acronym_str |
METC-1 |
network_name_str |
MedicalExpress (São Paulo. Online) |
repository_id_str |
|
spelling |
Clinical pharmacology of dobutamine and dopamine in preterm neonatesdobutaminedopaminehypotensionmetabolismneonatepharmacokineticsDobutamine is a β1 selective stimulant. β Receptor agonists are used to stimulate the rate and the force of cardiac contraction. The chronotropic effect is useful for the treatment of arrhythmias whereas the inotropic effect is useful to augment the myocardial contractility. Dobutamine is about four times as potent as dopamine in stimulating myocardial contractility in low concentrations and increases left ventricular output in the hypotensive preterm infants. Dobutamine possesses a center of asymmetry. The (-)-isomer of dobutamine is a potent agonist of α1 receptors and is capable of causing marked pressor responses. In contrast, (+)-dobutamine is a potent α1 receptor antagonist which can block the effects of (-)-dobutamine. Dobutamine is relatively cardioselective at dosages used in clinical practice with its main action being on β1-adrenergic receptors. Dobutamine and dopamine undergo intense metabolism in neonates where they are conjugated with sulphate and O-methylated. The clearance and the half-life of dobutamine and dopamine range over one order of magnitude in neonates. Dopamine is widely used to increase blood pressure, cardiac output, urine output and peripheral perfusion in neonates with shock and cardiac failure. Dopamine is more effective than dobutamine in the short-term treatment of systemic hypotension in preterm infants. High doses of dopamine cause vasoconstriction, increase systemic vascular resistance, and, eventually, decrease renal blood flow. Treatment with dobutamine is associated with a significantly greater increase in left ventricular output in the single study reporting that outcome. Dobutamine is indicated for the short-term treatment of cardiac decompensation.Mavera Edições Técnicas e Científicas Ltda2014-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000500275MedicalExpress v.1 n.5 2014reponame:MedicalExpress (São Paulo. Online)instname:Mavera Edições Científicas e Técnicas Ltda-MEinstacron:METC10.5935/MedicalExpress.2014.05.12info:eu-repo/semantics/openAccessPacifici,Gian Mariaeng2016-05-12T00:00:00Zoai:scielo:S2358-04292014000500275Revistahttp://www.medicalexpress.net.brhttps://old.scielo.br/oai/scielo-oai.php||medicalexpress@me.net.br2358-04292318-8111opendoar:2016-05-12T00:00MedicalExpress (São Paulo. Online) - Mavera Edições Científicas e Técnicas Ltda-MEfalse |
dc.title.none.fl_str_mv |
Clinical pharmacology of dobutamine and dopamine in preterm neonates |
title |
Clinical pharmacology of dobutamine and dopamine in preterm neonates |
spellingShingle |
Clinical pharmacology of dobutamine and dopamine in preterm neonates Pacifici,Gian Maria dobutamine dopamine hypotension metabolism neonate pharmacokinetics |
title_short |
Clinical pharmacology of dobutamine and dopamine in preterm neonates |
title_full |
Clinical pharmacology of dobutamine and dopamine in preterm neonates |
title_fullStr |
Clinical pharmacology of dobutamine and dopamine in preterm neonates |
title_full_unstemmed |
Clinical pharmacology of dobutamine and dopamine in preterm neonates |
title_sort |
Clinical pharmacology of dobutamine and dopamine in preterm neonates |
author |
Pacifici,Gian Maria |
author_facet |
Pacifici,Gian Maria |
author_role |
author |
dc.contributor.author.fl_str_mv |
Pacifici,Gian Maria |
dc.subject.por.fl_str_mv |
dobutamine dopamine hypotension metabolism neonate pharmacokinetics |
topic |
dobutamine dopamine hypotension metabolism neonate pharmacokinetics |
description |
Dobutamine is a β1 selective stimulant. β Receptor agonists are used to stimulate the rate and the force of cardiac contraction. The chronotropic effect is useful for the treatment of arrhythmias whereas the inotropic effect is useful to augment the myocardial contractility. Dobutamine is about four times as potent as dopamine in stimulating myocardial contractility in low concentrations and increases left ventricular output in the hypotensive preterm infants. Dobutamine possesses a center of asymmetry. The (-)-isomer of dobutamine is a potent agonist of α1 receptors and is capable of causing marked pressor responses. In contrast, (+)-dobutamine is a potent α1 receptor antagonist which can block the effects of (-)-dobutamine. Dobutamine is relatively cardioselective at dosages used in clinical practice with its main action being on β1-adrenergic receptors. Dobutamine and dopamine undergo intense metabolism in neonates where they are conjugated with sulphate and O-methylated. The clearance and the half-life of dobutamine and dopamine range over one order of magnitude in neonates. Dopamine is widely used to increase blood pressure, cardiac output, urine output and peripheral perfusion in neonates with shock and cardiac failure. Dopamine is more effective than dobutamine in the short-term treatment of systemic hypotension in preterm infants. High doses of dopamine cause vasoconstriction, increase systemic vascular resistance, and, eventually, decrease renal blood flow. Treatment with dobutamine is associated with a significantly greater increase in left ventricular output in the single study reporting that outcome. Dobutamine is indicated for the short-term treatment of cardiac decompensation. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-10-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000500275 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000500275 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.5935/MedicalExpress.2014.05.12 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Mavera Edições Técnicas e Científicas Ltda |
publisher.none.fl_str_mv |
Mavera Edições Técnicas e Científicas Ltda |
dc.source.none.fl_str_mv |
MedicalExpress v.1 n.5 2014 reponame:MedicalExpress (São Paulo. Online) instname:Mavera Edições Científicas e Técnicas Ltda-ME instacron:METC |
instname_str |
Mavera Edições Científicas e Técnicas Ltda-ME |
instacron_str |
METC |
institution |
METC |
reponame_str |
MedicalExpress (São Paulo. Online) |
collection |
MedicalExpress (São Paulo. Online) |
repository.name.fl_str_mv |
MedicalExpress (São Paulo. Online) - Mavera Edições Científicas e Técnicas Ltda-ME |
repository.mail.fl_str_mv |
||medicalexpress@me.net.br |
_version_ |
1754734596611637248 |